Journal article · 2006 · Open access
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
Health and Quality of Life Outcomes, 4(1), 79 · Published 11 October 2006 · DOI 10.1186/1477-7525-4-79
In brief
“Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance” is a 2006 journal article by For some treatment effects and 2 co-authors, published in Health and Quality of Life Outcomes. OpenAlex counts 3,631 citations as of 22 November 2026, which puts it in the top 1% of works published in 2006 by citations. It is open access under a CC BY licence: the full text is free to read at Health and Quality of Life Outcomes.
- Citations
- 3,631
- Most cited in
- 2023 (347)
- Field-weighted impact
- 98.79
- Authors
- 3
Abstract
This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
effects, F. S. T., example, T. P. I. T. O. S. O. D. F., & concepts., P. I. A. P. R. A. T. F. M. U. I. T. D. O. A. P. T. A. N. O. O. P. M. F. T. (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4(1), 79. https://doi.org/10.1186/1477-7525-4-79
MLA 9
effects, For some treatment, et al. “Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.” Health and Quality of Life Outcomes, vol. 4, no. 1, 2006, p. 79. https://doi.org/10.1186/1477-7525-4-79.
Chicago
effects, For some treatment, the patient is the only source of data. For example, and pain intensity and pain relief are the fundamental measures used in the development of analgesic products. There are no observable or physical measures for these concepts. 2006. “Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.” Health and Quality of Life Outcomes 4 (1): 79. https://doi.org/10.1186/1477-7525-4-79.
Harvard
effects, F. S. T., example, T. P. I. T. O. S. O. D. F. and concepts., P. I. A. P. R. A. T. F. M. U. I. T. D. O. A. P. T. A. N. O. O. P. M. F. T. (2006) ‘Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance’, Health and Quality of Life Outcomes, 4(1), p. 79. doi:10.1186/1477-7525-4-79.
IEEE
F. S. T. effects, T. P. I. T. O. S. O. D. F. example, and P. I. A. P. R. A. T. F. M. U. I. T. D. O. A. P. T. A. N. O. O. P. M. F. T. concepts., “Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance,” Health and Quality of Life Outcomes, vol. 4, no. 1, p. 79, 2006, doi: 10.1186/1477-7525-4-79.
BibTeX
@article{effects2006guidance,
title = {{Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance}},
author = {effects, For some treatment and example, the patient is the only source of data. For and concepts., pain intensity and pain relief are the fundamental measures used in the development of analgesic products. There are no observable or physical measures for these},
journal = {Health and Quality of Life Outcomes},
year = {2006},
volume = {4},
number = {1},
pages = {79},
doi = {10.1186/1477-7525-4-79},
url = {https://doi.org/10.1186/1477-7525-4-79}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 199 | |
| 2018 | 188 | |
| 2019 | 196 | |
| 2020 | 288 | |
| 2021 | 295 | |
| 2022 | 306 | |
| 2023 | 347 | |
| 2024 | 342 | |
| 2025 | 338 | |
| 2026 | 258 |
Its field-weighted citation impact is 98.79: it has been cited 98.79 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcome measures
- medical product development
- clinical trial endpoints
- quality of life
- patient perspectives
- regulatory review
- conceptual framework
- instrument validation
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
effects, F. S. T., example, T. P. I. T. O. S. O. D. F., & concepts., P. I. A. P. R. A. T. F. M. U. I. T. D. O. A. P. T. A. N. O. O. P. M. F. T. (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4(1), 79. https://doi.org/10.1186/1477-7525-4-79
How many times has this paper been cited?
3,631 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Health and Quality of Life Outcomes: sign in and open the PDF from this page.
Who wrote this paper?
For some treatment effects, the patient is the only source of data. For example, pain intensity and pain relief are the fundamental measures used in the development of analgesic products. There are no observable or physical measures for these concepts..
What is the DOI of this paper?
10.1186/1477-7525-4-79, permanently at https://doi.org/10.1186/1477-7525-4-79. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.